Last reviewed · How we verify
GSK1995057 single dose — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
GSK1995057 single dose (GSK1995057 single dose) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| GSK1995057 single dose TARGET | GSK1995057 single dose | GlaxoSmithKline | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- GSK1995057 single dose CI watch — RSS
- GSK1995057 single dose CI watch — Atom
- GSK1995057 single dose CI watch — JSON
- GSK1995057 single dose alone — RSS
Cite this brief
Drug Landscape (2026). GSK1995057 single dose — Competitive Intelligence Brief. https://druglandscape.com/ci/gsk1995057-single-dose. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing